Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE

OBJECTIVES: Evaluate the importance of treatment sequencing in SELECT-COMPARE, assessing potential differences between starting upadacitinib or adalimumab therapy following inadequate MTX response. METHODS: Patients from SELECT-COMPARE were randomized to upadacitinib 15 mg once daily, placebo or ada...

Descripción completa

Detalles Bibliográficos
Autores principales: Mysler, Eduardo, Tanaka, Yoshiya, Kavanaugh, Arthur, Aletaha, Daniel, Taylor, Peter C, Song, In-Ho, Shaw, Tim, Song, Yanna, DeMasi, Ryan, Ali, Mira, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152292/
https://www.ncbi.nlm.nih.gov/pubmed/36018230
http://dx.doi.org/10.1093/rheumatology/keac477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152292/
https://www.ncbi.nlm.nih.gov/pubmed/36018230
http://dx.doi.org/10.1093/rheumatology/keac477

Ejemplares similares